Boston Scientific Corporation
BSX
Hisse Senetlerindeki Sıralama
#409
Bu şirket açıklaması yalnızca İngilizce olarak sunulmaktadır.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Hisse Fiyatı
$41.88
Son senkronizasyon: 2026-10-30
Piyasa Değeri
$60.69B
Değişim (1 gün)
-1.89%
Değişim (1 yıl)
-58.42%
Ülke
US
Hisse senedi verileri: Financial Modeling Prep·Güncelleme: ·Yatırım tavsiyesi değildir·Nasıl hesaplıyoruz
Ticaret Boston Scientific Corporation (BSX)
Kategori
Healthcare
Boston Scientific Corporation (BSX) için kazanç
Sep 2026 itibarıyla kazanç TTM: $3.66B
Boston Scientific Corporation şirketinin en son finansal raporlarına göre, mevcut kazancı $3.66B'dir. 2025 yılında şirket $3.39B kazanç elde etti, bu 2024 yılındaki $2.28B kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Boston Scientific Corporation için kazanç geçmişi 2000 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değişim |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Boston Scientific Corporation net kârı hakkında sorular
Boston Scientific Corporation net kârı ne kadar?
Eyl 2026 itibarıyla Boston Scientific Corporation net kârı son on iki ayda $3.66B oldu.
Boston Scientific Corporation net kârı 2025 yılında ne kadardı?
2025 yılında Boston Scientific Corporation net kârı, 2024 yılına ($2.28B) göre 48.33% artarak $3.39B oldu.
Boston Scientific Corporation net kârı 2020 yılından bu yana nasıl değişti?
2020–2025 döneminde Boston Scientific Corporation net kârı en yüksek seviyesini 2025 yılında ($3.39B), en düşük seviyesini ise 2020 yılında ($-79.00M) gördü.
Boston Scientific Corporation net kârı benzer şirketlerle karşılaştırıldığında nasıl?
Boston Scientific Corporation net kârı ($3.66B), yukarıda listelenen 5 benzer şirketin 2 tanesinden daha yüksek. Bu şirketler arasında en yüksek değer $6.60B ile Medtronic plc şirketine ait.